Abstract
In Germany, the recently approved 20-valent pneumococcal conjugate vaccine had a substantially higher coverage against pneumonia in adults than the 13-valent vaccine, while the coverage gap compared to the 23-valent polysaccharide vaccine was small https://bit.ly/3q4skov
| Original language | English |
|---|---|
| Journal | European Respiratory Journal |
| Volume | 59 |
| Issue number | 2 |
| ISSN | 0903-1936 |
| DOIs | |
| Publication status | Published - 01.02.2022 |
Funding
(CM-COVID). This study was supported by an unrestricted grant from Pfizer. Teva, and research funding from Actelion, Bayer Health Care, Biotest, partly supported by a grant of the Federal Ministry of Education and Research
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)